Remove Business Development Remove Development Remove Pharma Companies
article thumbnail

Pfizer hires Citi analyst Andrew Baum to manage portfolio strategy, business development

Fierce Pharma

“Our next question will come from Andrew Baum with Citi.” | Citi analyst Andrew Baum, after covering Pfizer for more than a decade, will join the Big Pharma company as chief strategy and innovation officer. In the role, he'll oversee the drugmaker's portfolio management and business development activities.

article thumbnail

How Are Biopharma Companies Evaluating Partnerships in the Rare Disease Space?

Camargo

Thomas Kassberg, Chief Business Officer, Ultragenyx. Thomas Kassberg, Chief Business Officer, Ultragenyx. I think you really need to get the feedback directly from patients and then incorporate that feedback as you think about how you’re going to develop the product to be successful. Tom Kassberg, Ultragenyx. Dan Curran, Takeda.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading pharmaceutical solid dose (commercial dose) manufacturing companies in contract marketing

Pharmaceutical Technology

Streamlined development, flexibility in manufacturing, and improved product quality at reduced costs, while gaining access to capabilities and capacity are some of the factors fuelling the pharmaceutical solid dosage contract manufacturing market.

article thumbnail

VivoPlex raises funding to develop intra-uterine sensor

pharmaphorum

to develop an intra-uterine sensor system and generate clinical data that could be used for European approval. The Future Fund participated in the second tranche of the fundraising alongside other investors, unlocking matched financing and helping to drive the business forward towards commercialisation.

article thumbnail

Synthetic control arms in clinical trials: Making it happen

pharmaphorum

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials. His research focuses on the development of big data machine learning for tracking the health of complex systems. But what does it take to implement these innovations?

article thumbnail

Merck confirms $11.5bn Acceleron takeover deal

pharmaphorum

.” It also said that “strategic business development” is a top priority for the company at the moment, reflecting a longstanding concern that it has become over-reliant on Keytruda and needs to diversify.

Sales 117
article thumbnail

COVID-19 underscores need to boost pharma manufacturing in emerging markets

pharmaphorum

For the past year, life science companies around the world worked at breakneck speed to develop and manufacture safe and effective treatments to respond to the COVID-19 pandemic. India and China have seen the emergence of strong, local pharma companies. The right answer requires upfront analysis.